Literature DB >> 24275638

Development of lentiviral vectors for transient and stable protein overexpression in mammalian cells. A new strategy for recombinant human FVIII (rhFVIII) production.

Eduardo Federico Mufarrege1, Sebastián Antuña2, Marina Etcheverrigaray2, Ricardo Kratje2, Claudio Prieto2.   

Abstract

BACKGROUND: Recombinant protein overexpression in mammalian cells constitutes a real challenge in therapeutic protein production. Following the discovery of intron functionality in gene expression, various expression vectors that include them in their sequences have been developed. In this study, the main goal was to develop new lentiviral vectors (LVs) carrying different promoter and intron-containing 5'UTR (5' untranslated region) combinations and the design of LVs for rhFVIII production in Chinese hamster ovary (CHO) cells.
RESULTS: By combining the human cytomegalovirus (CMV) or the elongation factor 1α (EF-1α) promoters along with different 5'UTRs that included leader introns, between 2 and 12-fold increases were reached, when transient and stable expression of the enhanced green fluorescent protein (EGFP) and rhFVIII were analyzed. Also, new LVs provided with promoters and 5'UTRs from high expression genes, according to a gene database, were designed. Three of them were shown to be superior to the EF-1α promoter in three widely used cell lines.
CONCLUSION: In the present work, LVs containing different promoters and 5'UTRs were designed. In transient and stable assays some of these constructs have shown higher activity compared with commercial promoters and, therefore, constitute promising candidates for therapeutic protein production.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CMV enhancer/promoter; EF-1α promoter; Lentiviral vector; Protein overexpression; rhFVIII production

Mesh:

Substances:

Year:  2013        PMID: 24275638     DOI: 10.1016/j.pep.2013.11.005

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  3 in total

1.  Effect of transmembrane pressure on Factor VIII yield in ATF perfusion culture for the production of recombinant human Factor VIII co-expressed with von Willebrand factor.

Authors:  Seung-Chul Kim; Sora An; Hyun-Ki Kim; Beom-Soo Park; Kyu-Heum Na; Byung-Gee Kim
Journal:  Cytotechnology       Date:  2015-10-13       Impact factor: 2.058

Review 2.  Production of Therapeutic Enzymes by Lentivirus Transgenesis.

Authors:  María Celeste Rodríguez; Natalia Ceaglio; Sebastián Antuña; María Belén Tardivo; Marina Etcheverrigaray; Claudio Prieto
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

3.  Enhancing arginase 2 expression using target site blockers as a strategy to modulate macrophage phenotype.

Authors:  Chiara De Santi; Frances K Nally; Remsha Afzal; Conor P Duffy; Stephen Fitzsimons; Stephanie L Annett; Tracy Robson; Jennifer K Dowling; Sally-Ann Cryan; Claire E McCoy
Journal:  Mol Ther Nucleic Acids       Date:  2022-08-04       Impact factor: 10.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.